Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 29 entries
Sorted by: Best Match Show Resources per page
Cancer immunotherapy: Re-programming cells of the innate and adaptive immune systems.

Oncoimmunology

Manjili MH, Payne KK.
PMID: 22720242
Oncoimmunology. 2012 Mar 01;1(2):201-204. doi: 10.4161/onci.1.2.18113.

Cancers utilize multiple mechanisms to overcome immune responses. Emerging evidence suggest that immunotherapy of cancer should focus on inducing and re-programming cells of the innate and adaptive immune systems rather than focusing solely on T cells. Recently, we have...

Cite
Manjili MH, Payne KK. Cancer immunotherapy: Re-programming cells of the innate and adaptive immune systems. Oncoimmunology. 2012;1(2):201-204doi: 10.4161/onci.1.2.18113.
Manjili, M. H., & Payne, K. K. (2012). Cancer immunotherapy: Re-programming cells of the innate and adaptive immune systems. Oncoimmunology, 1(2), 201-204. https://doi.org/10.4161/onci.1.2.18113
Manjili, Masoud H, and Payne, Kyle K. "Cancer immunotherapy: Re-programming cells of the innate and adaptive immune systems." Oncoimmunology vol. 1,2 (2012): 201-204. doi: https://doi.org/10.4161/onci.1.2.18113
Manjili MH, Payne KK. Cancer immunotherapy: Re-programming cells of the innate and adaptive immune systems. Oncoimmunology. 2012 Mar 01;1(2):201-204. doi: 10.4161/onci.1.2.18113. PMID: 22720242; PMCID: PMC3377002.
Copy Download .nbib Format: NLM
Stem cell transplantation as a dynamical system: are clinical outcomes deterministic?.

Frontiers in immunology

Toor AA, Kobulnicky JD, Salman S, Roberts CH, Jameson-Lee M, Meier J, Scalora A, Sheth N, Koparde V, Serrano M, Buck GA, Clark WB, McCarty JM, Chung HM, Manjili MH, Sabo RT, Neale MC.
PMID: 25520720
Front Immunol. 2014 Dec 03;5:613. doi: 10.3389/fimmu.2014.00613. eCollection 2014.

Outcomes in stem cell transplantation (SCT) are modeled using probability theory. However, the clinical course following SCT appears to demonstrate many characteristics of dynamical systems, especially when outcomes are considered in the context of immune reconstitution. Dynamical systems tend...

Cite
Toor AA, Kobulnicky JD, Salman S, et al. Stem cell transplantation as a dynamical system: are clinical outcomes deterministic?. Front Immunol. 2014;5:613doi: 10.3389/fimmu.2014.00613.
Toor, A. A., Kobulnicky, J. D., Salman, S., Roberts, C. H., Jameson-Lee, M., Meier, J., Scalora, A., Sheth, N., Koparde, V., Serrano, M., Buck, G. A., Clark, W. B., McCarty, J. M., Chung, H. M., Manjili, M. H., Sabo, R. T., & Neale, M. C. (2014). Stem cell transplantation as a dynamical system: are clinical outcomes deterministic?. Frontiers in immunology, 5613. https://doi.org/10.3389/fimmu.2014.00613
Toor, Amir A, et al. "Stem cell transplantation as a dynamical system: are clinical outcomes deterministic?." Frontiers in immunology vol. 5 (2014): 613. doi: https://doi.org/10.3389/fimmu.2014.00613
Toor AA, Kobulnicky JD, Salman S, Roberts CH, Jameson-Lee M, Meier J, Scalora A, Sheth N, Koparde V, Serrano M, Buck GA, Clark WB, McCarty JM, Chung HM, Manjili MH, Sabo RT, Neale MC. Stem cell transplantation as a dynamical system: are clinical outcomes deterministic?. Front Immunol. 2014 Dec 03;5:613. doi: 10.3389/fimmu.2014.00613. eCollection 2014. PMID: 25520720; PMCID: PMC4253954.
Copy Download .nbib Format: NLM
Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy.

Oncotarget

Aqbi HF, Tyutyunyk-Massey L, Keim RC, Butler SE, Thekkudan T, Joshi S, Smith TM, Bandyopadhyay D, Idowu MO, Bear HD, Payne KK, Gewirtz DA, Manjili MH.
PMID: 29774126
Oncotarget. 2018 Apr 24;9(31):22113-22122. doi: 10.18632/oncotarget.25197. eCollection 2018 Apr 24.

Breast cancer patients who initially respond to cancer therapies often succumb to distant recurrence of the disease. It is not clear why people with the same type of breast cancer respond to treatments differently; some escape from dormancy and...

Cite
Aqbi HF, Tyutyunyk-Massey L, Keim RC, et al. Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy. Oncotarget. 2018;9(31):22113-22122doi: 10.18632/oncotarget.25197.
Aqbi, H. F., Tyutyunyk-Massey, L., Keim, R. C., Butler, S. E., Thekkudan, T., Joshi, S., Smith, T. M., Bandyopadhyay, D., Idowu, M. O., Bear, H. D., Payne, K. K., Gewirtz, D. A., & Manjili, M. H. (2018). Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy. Oncotarget, 9(31), 22113-22122. https://doi.org/10.18632/oncotarget.25197
Aqbi, Hussein F, et al. "Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy." Oncotarget vol. 9,31 (2018): 22113-22122. doi: https://doi.org/10.18632/oncotarget.25197
Aqbi HF, Tyutyunyk-Massey L, Keim RC, Butler SE, Thekkudan T, Joshi S, Smith TM, Bandyopadhyay D, Idowu MO, Bear HD, Payne KK, Gewirtz DA, Manjili MH. Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy. Oncotarget. 2018 Apr 24;9(31):22113-22122. doi: 10.18632/oncotarget.25197. eCollection 2018 Apr 24. PMID: 29774126; PMCID: PMC5955162.
Copy Download .nbib Format: NLM
Methotrexate-conjugated L-lysine coated iron oxide magnetic nanoparticles for inhibition of MCF-7 breast cancer cells.

Drug development and industrial pharmacy

Nosrati H, Salehiabar M, Davaran S, Danafar H, Manjili HK.
PMID: 29280388
Drug Dev Ind Pharm. 2018 Jun;44(6):886-894. doi: 10.1080/03639045.2017.1417422. Epub 2017 Dec 27.

Methotrexate (MTX), a stoichiometric inhibitor of dihydrofolate reductase enzyme, is a chemotherapeutic agent for treating a diversity of neoplasms. In this study, we design and developed a new formulation of MTX that serves as drug carrier and examined its...

Cite
Nosrati H, Salehiabar M, Davaran S, et al. Methotrexate-conjugated L-lysine coated iron oxide magnetic nanoparticles for inhibition of MCF-7 breast cancer cells. Drug Dev Ind Pharm. 2017;44(6):886-894doi: 10.1080/03639045.2017.1417422.
Nosrati, H., Salehiabar, M., Davaran, S., Danafar, H., & Manjili, H. K. (2018). Methotrexate-conjugated L-lysine coated iron oxide magnetic nanoparticles for inhibition of MCF-7 breast cancer cells. Drug development and industrial pharmacy, 44(6), 886-894. https://doi.org/10.1080/03639045.2017.1417422
Nosrati, Hamed, et al. "Methotrexate-conjugated L-lysine coated iron oxide magnetic nanoparticles for inhibition of MCF-7 breast cancer cells." Drug development and industrial pharmacy vol. 44,6 (2018): 886-894. doi: https://doi.org/10.1080/03639045.2017.1417422
Nosrati H, Salehiabar M, Davaran S, Danafar H, Manjili HK. Methotrexate-conjugated L-lysine coated iron oxide magnetic nanoparticles for inhibition of MCF-7 breast cancer cells. Drug Dev Ind Pharm. 2018 Jun;44(6):886-894. doi: 10.1080/03639045.2017.1417422. Epub 2017 Dec 27. PMID: 29280388.
Copy Download .nbib Format: NLM
Erratum to: Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals".

Breast cancer research and treatment

Manjili MH, Arnouk H, Knutson KL, Kmieciak M, Disis ML, Subjeck JR, Kazim AL.
PMID: 28303485
Breast Cancer Res Treat. 2006 Apr;96(3):243. doi: 10.1007/s10549-006-9163-6. Epub 2006 Mar 16.

No abstract available.

Cite
Manjili MH, Arnouk H, Knutson KL, et al. Erratum to: Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals". Breast Cancer Res Treat. 2006;96(3):243doi: 10.1007/s10549-006-9163-6.
Manjili, M. H., Arnouk, H., Knutson, K. L., Kmieciak, M., Disis, M. L., Subjeck, J. R., & Kazim, A. L. (2006). Erratum to: Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals". Breast cancer research and treatment, 96(3), 243. https://doi.org/10.1007/s10549-006-9163-6
Manjili, Masoud H, et al. "Erratum to: Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals"." Breast cancer research and treatment vol. 96,3 (2006): 243. doi: https://doi.org/10.1007/s10549-006-9163-6
Manjili MH, Arnouk H, Knutson KL, Kmieciak M, Disis ML, Subjeck JR, Kazim AL. Erratum to: Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals". Breast Cancer Res Treat. 2006 Apr;96(3):243. doi: 10.1007/s10549-006-9163-6. Epub 2006 Mar 16. PMID: 28303485.
Copy Download .nbib Format: NLM
In vivo and in vitro biocompatibility study of novel microemulsion hybridized with bovine serum albumin as nanocarrier for drug delivery.

Heliyon

Gharbavi M, Manjili HK, Amani J, Sharafi A, Danafar H.
PMID: 31198875
Heliyon. 2019 Jun 06;5(6):e01858. doi: 10.1016/j.heliyon.2019.e01858. eCollection 2019 Jun.

The present study aimed to synthesize triacetin-microemulsion (T-ME) and T-ME hybridized with bovine serum albumin nanoparticles (T-BSA-ME) having narrow particle size distribution and versatile carrier systems as a novel microemulsion system. The suggested ME system was characterized by Fourier...

Cite
Gharbavi M, Manjili HK, Amani J, et al. In vivo and in vitro biocompatibility study of novel microemulsion hybridized with bovine serum albumin as nanocarrier for drug delivery. Heliyon. 2019;5(6):e01858doi: 10.1016/j.heliyon.2019.e01858.
Gharbavi, M., Manjili, H. K., Amani, J., Sharafi, A., & Danafar, H. (2019). In vivo and in vitro biocompatibility study of novel microemulsion hybridized with bovine serum albumin as nanocarrier for drug delivery. Heliyon, 5(6), e01858. https://doi.org/10.1016/j.heliyon.2019.e01858
Gharbavi, Mahmoud, et al. "In vivo and in vitro biocompatibility study of novel microemulsion hybridized with bovine serum albumin as nanocarrier for drug delivery." Heliyon vol. 5,6 (2019): e01858. doi: https://doi.org/10.1016/j.heliyon.2019.e01858
Gharbavi M, Manjili HK, Amani J, Sharafi A, Danafar H. In vivo and in vitro biocompatibility study of novel microemulsion hybridized with bovine serum albumin as nanocarrier for drug delivery. Heliyon. 2019 Jun 06;5(6):e01858. doi: 10.1016/j.heliyon.2019.e01858. eCollection 2019 Jun. PMID: 31198875; PMCID: PMC6556858.
Copy Download .nbib Format: NLM
Tumor Cell Dormancy: Threat or Opportunity in the Fight against Cancer.

Cancers

Jahanban-Esfahlan R, Seidi K, Manjili MH, Jahanban-Esfahlan A, Javaheri T, Zare P.
PMID: 31430951
Cancers (Basel). 2019 Aug 19;11(8). doi: 10.3390/cancers11081207.

Tumor dormancy, a clinically undetectable state of cancer, makes a major contribution to the development of multidrug resistance (MDR), minimum residual disease (MRD), tumor outgrowth, cancer relapse, and metastasis. Despite its high incidence, the whole picture of dormancy-regulated molecular...

Cite
Jahanban-Esfahlan R, Seidi K, Manjili MH, et al. Tumor Cell Dormancy: Threat or Opportunity in the Fight against Cancer. Cancers (Basel). 2019;11(8)doi: 10.3390/cancers11081207.
Jahanban-Esfahlan, R., Seidi, K., Manjili, M. H., Jahanban-Esfahlan, A., Javaheri, T., & Zare, P. (2019). Tumor Cell Dormancy: Threat or Opportunity in the Fight against Cancer. Cancers, 11(8), . https://doi.org/10.3390/cancers11081207
Jahanban-Esfahlan, Rana, et al. "Tumor Cell Dormancy: Threat or Opportunity in the Fight against Cancer." Cancers vol. 11,8 (2019). doi: https://doi.org/10.3390/cancers11081207
Jahanban-Esfahlan R, Seidi K, Manjili MH, Jahanban-Esfahlan A, Javaheri T, Zare P. Tumor Cell Dormancy: Threat or Opportunity in the Fight against Cancer. Cancers (Basel). 2019 Aug 19;11(8). doi: 10.3390/cancers11081207. PMID: 31430951; PMCID: PMC6721805.
Copy Download .nbib Format: NLM
IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression.

Journal of leukocyte biology

Aqbi HF, Wallace M, Sappal S, Payne KK, Manjili MH.
PMID: 29469956
J Leukoc Biol. 2018 Feb 22; doi: 10.1002/JLB.5MIR0917-351R. Epub 2018 Feb 22.

Tumor immunoediting consisting of three phases of elimination, equilibrium or dormancy, and escape has been supported by preclinical and clinical data. A comprehensive understanding of the molecular mechanisms by which antitumor immune responses regulate these three phases are important...

Cite
Aqbi HF, Wallace M, Sappal S, et al. IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression. J Leukoc Biol. 2018;doi: 10.1002/JLB.5MIR0917-351R.
Aqbi, H. F., Wallace, M., Sappal, S., Payne, K. K., & Manjili, M. H. (2018). IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression. Journal of leukocyte biology, . https://doi.org/10.1002/JLB.5MIR0917-351R
Aqbi, Hussein F, et al. "IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression." Journal of leukocyte biology vol. (2018). doi: https://doi.org/10.1002/JLB.5MIR0917-351R
Aqbi HF, Wallace M, Sappal S, Payne KK, Manjili MH. IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression. J Leukoc Biol. 2018 Feb 22; doi: 10.1002/JLB.5MIR0917-351R. Epub 2018 Feb 22. PMID: 29469956; PMCID: PMC6157004.
Copy Download .nbib Format: NLM
In silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem-Cell Transplant Donors and Recipients: Understanding the Quantitative Immunobiology of Allogeneic Transplantation.

Frontiers in immunology

Jameson-Lee M, Koparde V, Griffith P, Scalora AF, Sampson JK, Khalid H, Sheth NU, Batalo M, Serrano MG, Roberts CH, Hess ML, Buck GA, Neale MC, Manjili MH, Toor AA.
PMID: 25414699
Front Immunol. 2014 Nov 06;5:529. doi: 10.3389/fimmu.2014.00529. eCollection 2014.

Donor T-cell mediated graft versus host (GVH) effects may result from the aggregate alloreactivity to minor histocompatibility antigens (mHA) presented by the human leukocyte antigen (HLA) molecules in each donor-recipient pair undergoing stem-cell transplantation (SCT). Whole exome sequencing has...

Cite
Jameson-Lee M, Koparde V, Griffith P, et al. In silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem-Cell Transplant Donors and Recipients: Understanding the Quantitative Immunobiology of Allogeneic Transplantation. Front Immunol. 2014;5:529doi: 10.3389/fimmu.2014.00529.
Jameson-Lee, M., Koparde, V., Griffith, P., Scalora, A. F., Sampson, J. K., Khalid, H., Sheth, N. U., Batalo, M., Serrano, M. G., Roberts, C. H., Hess, M. L., Buck, G. A., Neale, M. C., Manjili, M. H., & Toor, A. A. (2014). In silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem-Cell Transplant Donors and Recipients: Understanding the Quantitative Immunobiology of Allogeneic Transplantation. Frontiers in immunology, 5529. https://doi.org/10.3389/fimmu.2014.00529
Jameson-Lee, Max, et al. "In silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem-Cell Transplant Donors and Recipients: Understanding the Quantitative Immunobiology of Allogeneic Transplantation." Frontiers in immunology vol. 5 (2014): 529. doi: https://doi.org/10.3389/fimmu.2014.00529
Jameson-Lee M, Koparde V, Griffith P, Scalora AF, Sampson JK, Khalid H, Sheth NU, Batalo M, Serrano MG, Roberts CH, Hess ML, Buck GA, Neale MC, Manjili MH, Toor AA. In silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem-Cell Transplant Donors and Recipients: Understanding the Quantitative Immunobiology of Allogeneic Transplantation. Front Immunol. 2014 Nov 06;5:529. doi: 10.3389/fimmu.2014.00529. eCollection 2014. PMID: 25414699; PMCID: PMC4222229.
Copy Download .nbib Format: NLM
Co-delivery of siRNA and lycopene encapsulated hybrid lipid nanoparticles for dual silencing of insulin-like growth factor 1 receptor in MCF-7 breast cancer cell line.

International journal of biological macromolecules

Mennati A, Rostamizadeh K, Manjili HK, Fathi M, Danafar H.
PMID: 34999039
Int J Biol Macromol. 2022 Jan 06; doi: 10.1016/j.ijbiomac.2021.12.197. Epub 2022 Jan 06.

Insulin-like growth factor-1 receptor (IGF-1R) is expressed in malignant and normal breast tissue, and its intermittent activation by multiple IGF-1 signaling pathways leads to neoplasm cell proliferation, impaired apoptosis, increased survival, and resistance to cytotoxic therapeutic agents. Therefore, simultaneous...

Cite
Mennati A, Rostamizadeh K, Manjili HK, et al. Co-delivery of siRNA and lycopene encapsulated hybrid lipid nanoparticles for dual silencing of insulin-like growth factor 1 receptor in MCF-7 breast cancer cell line. Int J Biol Macromol. 2022;doi: 10.1016/j.ijbiomac.2021.12.197.
Mennati, A., Rostamizadeh, K., Manjili, H. K., Fathi, M., & Danafar, H. (2022). Co-delivery of siRNA and lycopene encapsulated hybrid lipid nanoparticles for dual silencing of insulin-like growth factor 1 receptor in MCF-7 breast cancer cell line. International journal of biological macromolecules, . https://doi.org/10.1016/j.ijbiomac.2021.12.197
Mennati, Afsaneh, et al. "Co-delivery of siRNA and lycopene encapsulated hybrid lipid nanoparticles for dual silencing of insulin-like growth factor 1 receptor in MCF-7 breast cancer cell line." International journal of biological macromolecules vol. (2022). doi: https://doi.org/10.1016/j.ijbiomac.2021.12.197
Mennati A, Rostamizadeh K, Manjili HK, Fathi M, Danafar H. Co-delivery of siRNA and lycopene encapsulated hybrid lipid nanoparticles for dual silencing of insulin-like growth factor 1 receptor in MCF-7 breast cancer cell line. Int J Biol Macromol. 2022 Jan 06; doi: 10.1016/j.ijbiomac.2021.12.197. Epub 2022 Jan 06. PMID: 34999039.
Copy Download .nbib Format: NLM
HLA-DR expression on myeloid cells is a potential prognostic factor in patients with high-risk neuroblastoma.

Oncoimmunology

Gowda M, Payne KK, Godder K, Manjili MH.
PMID: 24349875
Oncoimmunology. 2013 Oct 01;2(10):e26616. doi: 10.4161/onci.26616. Epub 2013 Oct 10.

The adaptive immune system has been reported to play a dual role in many cancers, on one hand inhibiting tumor growth and, on the other hand, promoting disease progression, escape from cancer immunosurveillance and relapse. We have previously reported...

Cite
Gowda M, Payne KK, Godder K, et al. HLA-DR expression on myeloid cells is a potential prognostic factor in patients with high-risk neuroblastoma. Oncoimmunology. 2013;2(10):e26616doi: 10.4161/onci.26616.
Gowda, M., Payne, K. K., Godder, K., & Manjili, M. H. (2013). HLA-DR expression on myeloid cells is a potential prognostic factor in patients with high-risk neuroblastoma. Oncoimmunology, 2(10), e26616. https://doi.org/10.4161/onci.26616
Gowda, Madhu, et al. "HLA-DR expression on myeloid cells is a potential prognostic factor in patients with high-risk neuroblastoma." Oncoimmunology vol. 2,10 (2013): e26616. doi: https://doi.org/10.4161/onci.26616
Gowda M, Payne KK, Godder K, Manjili MH. HLA-DR expression on myeloid cells is a potential prognostic factor in patients with high-risk neuroblastoma. Oncoimmunology. 2013 Oct 01;2(10):e26616. doi: 10.4161/onci.26616. Epub 2013 Oct 10. PMID: 24349875; PMCID: PMC3857328.
Copy Download .nbib Format: NLM
Development of a Novel Proteomic Risk-Classifier for Prognostication of Patients With Early-Stage Hormone Receptor-Positive Breast Cancer.

Biomarker insights

Ramkumar C, Buturovic L, Malpani S, Kumar Attuluri A, Basavaraj C, Prakash C, Madhav L, Doval DC, Mehta A, Bakre MM.
PMID: 30083053
Biomark Insights. 2018 Jul 30;13:1177271918789100. doi: 10.1177/1177271918789100. eCollection 2018.

Use of proteomic strategies to identify a risk classifier that estimates probability of distant recurrence in early-stage hormone receptor (HR)-positive breast cancer is relevant to physiological cellular function and therefore to intrinsic tumor biology. We used a 298-sample retrospective...

Cite
Ramkumar C, Buturovic L, Malpani S, et al. Development of a Novel Proteomic Risk-Classifier for Prognostication of Patients With Early-Stage Hormone Receptor-Positive Breast Cancer. Biomark Insights. 2018;13:1177271918789100doi: 10.1177/1177271918789100.
Ramkumar, C., Buturovic, L., Malpani, S., Kumar Attuluri, A., Basavaraj, C., Prakash, C., Madhav, L., Doval, D. C., Mehta, A., & Bakre, M. M. (2018). Development of a Novel Proteomic Risk-Classifier for Prognostication of Patients With Early-Stage Hormone Receptor-Positive Breast Cancer. Biomarker insights, 131177271918789100. https://doi.org/10.1177/1177271918789100
Ramkumar, Charusheila, et al. "Development of a Novel Proteomic Risk-Classifier for Prognostication of Patients With Early-Stage Hormone Receptor-Positive Breast Cancer." Biomarker insights vol. 13 (2018): 1177271918789100. doi: https://doi.org/10.1177/1177271918789100
Ramkumar C, Buturovic L, Malpani S, Kumar Attuluri A, Basavaraj C, Prakash C, Madhav L, Doval DC, Mehta A, Bakre MM. Development of a Novel Proteomic Risk-Classifier for Prognostication of Patients With Early-Stage Hormone Receptor-Positive Breast Cancer. Biomark Insights. 2018 Jul 30;13:1177271918789100. doi: 10.1177/1177271918789100. eCollection 2018. PMID: 30083053; PMCID: PMC6066801.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 29 entries